RGC NASDAQ
Regencell Bioscience Holdings Limited
1W: +10.5%
1M: +8.1%
3M: +21.6%
YTD: -66.8%
1Y: -56.9%
3Y: +1497.8%
5Y: +749.7%
$6.82
+0.49 (+7.74%)
Weekly Expected Move ±10.5%
$5
$6
$7
$8
$8
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$393K
+47.3% ▲
Operating Income
-$4M
+20.4% ▲
Net Income
-$4M
+16.7% ▲
EPS (Diluted)
$-0.01
+17.2% ▲
EBITDA
-$3M
+11.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $26K | $604K | $770K | $746K | $393K |
| Gross Profit | -$26K | -$604K | -$770K | -$746K | -$393K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $438K | $3M | $2M | $1M | $948K |
| SG&A Expenses | $943K | $5M | $5M | $3M | $2M |
| Operating Expenses | $1M | $8M | $6M | $4M | $3M |
| Operating Income | -$1M | -$8M | -$6M | -$5M | -$4M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$1M | -$8M | -$6M | -$4M | -$4M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$1M | -$7M | -$6M | -$4M | -$4M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| EBITDA | -$1M | -$7M | -$5M | -$4M | -$3M |
| Shares Outstanding | 480M | 494M | 494M | 494M | 494M |